Literature DB >> 4843236

Studies on digitalis. II. The influence of impaired renal function on the renal excretion of digitoxin and its cardioactive metabolites.

L Storstein.   

Abstract

Entities:  

Mesh:

Substances:

Year:  1974        PMID: 4843236     DOI: 10.1002/cpt1974161part125

Source DB:  PubMed          Journal:  Clin Pharmacol Ther        ISSN: 0009-9236            Impact factor:   6.875


× No keyword cloud information.
  10 in total

Review 1.  Critical compilation of terminal half-lives, percent excreted unchanged, and changes of half-life in renal and hepatic dysfunction for studies in humans with references.

Authors:  L A Pagliaro; L Z Benet
Journal:  J Pharmacokinet Biopharm       Date:  1975-10

2.  Clinical pharmacokinetics of the nifedipine/co-dergocrine combination in impaired liver and renal function.

Authors:  W Kirch; A Nokhodian; A Halabi; G Weidinger
Journal:  Eur J Drug Metab Pharmacokinet       Date:  1992 Jan-Mar       Impact factor: 2.441

3.  Drug kinetics and artificial kidneys.

Authors:  T B Gibson; H A Nelson
Journal:  Clin Pharmacokinet       Date:  1977 Nov-Dec       Impact factor: 6.447

4.  Clinical pharmacokinetics of digitoxin.

Authors:  D Perrier; M Mayersohn; F I Marcus
Journal:  Clin Pharmacokinet       Date:  1977 Jul-Aug       Impact factor: 6.447

Review 5.  Clinical pharmacokinetics of cardiac glycosides in patients with renal dysfunction.

Authors:  J K Aronson
Journal:  Clin Pharmacokinet       Date:  1983 Mar-Apr       Impact factor: 6.447

Review 6.  Disease-related alterations in cardiac glycoside disposition.

Authors:  H R Ochs; D J Greenblatt; G Bodem; H J Dengler
Journal:  Clin Pharmacokinet       Date:  1982 Sep-Oct       Impact factor: 6.447

7.  A standard approach to compiling clinical pharmacokinetic data.

Authors:  L B Sheiner; L Z Benet; L A Pagliaro
Journal:  J Pharmacokinet Biopharm       Date:  1981-02

8.  The effect of age on digitoxin pharmacokinetics.

Authors:  M A Donovan; C M Castleden; J E Pohl; C A Kraft
Journal:  Br J Clin Pharmacol       Date:  1981-04       Impact factor: 4.335

9.  Digitoxin and its metabolites in patients with liver cirrhosis.

Authors:  A Nokhodian; S R Santos; W Kirch
Journal:  Eur J Drug Metab Pharmacokinet       Date:  1993 Apr-Jun       Impact factor: 2.441

10.  Disposition, Elimination and Haemodynamic Effects of Gallopamil in Patients with Fatty Liver Disease.

Authors:  M Siepmann; B R Rao; W Kirch
Journal:  Clin Drug Investig       Date:  1995-12       Impact factor: 2.859

  10 in total

北京卡尤迪生物科技股份有限公司 © 2022-2023.